Hot Investor Mandate: China-Headquartered Pharmaceutical’s Investment Arm Actively Seeks Opportunities in Novel Drugs Including Cell & Gene Therapy, Biologics, and More

10 Jun

A large pharmaceutical headquartered in China with more than 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.) has their main business covering chemical and biological medicines, pharmaceutical packaging, and trading.

The investment subsidiary of this pharmaceutical has 200 million RMB assets under management, and is looking for investment and in-licensing opportunities in novel drug research and development.  The firm also invests in funds. The firm’s allocation size is decided case by case.

The firm is most interested in companies developing novel drugs in biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. The firm is interested in distribution rights. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: